HCWB · HCW Biologics Inc.

HCW Biologics Inc. is a clinical-stage biopharmaceutical company developing fusion immunotherapeutics for chronic inflammation, autoimmune disorders, and cancer. The company is offering up to 13,625,304 shares of common stock at an assumed price of $0.411 per share, with gross proceeds of up to $5.6 million. Net proceeds are estimated at $5.2 million, which will be used to fund clinical trials for HCW9302 (alopecia areata), IND-enabling studies, marketing, trade payables, and general corporate purposes. The offering is conducted on a reasonable best-efforts basis with no minimum, meaning the company may raise significantly less.

Financially, as of December 31, 2025, HCW Biologics had $1.95 million in cash and an accumulated deficit of $108.5 million. The company has not generated revenue from product sales and relies on equity and debt financing. The as-adjusted net tangible book value per share after the offering is $0.49, resulting in immediate dilution of $0.08 per share for new investors.

Key risks include Nasdaq non-compliance: the company received a notice for failing to maintain a minimum bid price of $1.00 per share and has a hearing scheduled for May 5, 2026. Additionally, the company is subject to a mandatory panel monitor period. The offering's lack of a minimum could leave the company undercapitalized. Management has broad discretion over proceeds, and the pre-funded warrants offered have no trading market.

Management is led by Dr. Hing C. Wong, who previously developed Anktiva® (sold for $1.0 billion). Other executives include CFO Rebecca Byam (former PwC director) and CSO Peter Rhode (former Altor BioScience SVP). Directors and officers intend to purchase $430,000 of securities in the offering, aligning interests.

Overall, this offering is critical for HCW Biologics to fund operations and clinical development, but it carries significant risks related to dilution, Nasdaq listing, and uncertain proceeds.